Fertility startup Inito wants to use AI-designed antibodies to expand at-home health tests

Fertility startup Inito has raised $29 million in Series B funding to scale its at-home health diagnostics platform and use AI-designed antibodies to unlock new kinds of at-home tests. 

When the company launched its first fertility monitor in 2021, its goal was to make quantitative fertility hormone testing possible at home. 

While standard at-home ovulation tests predict fertile days by tracking estrogen and Luteinizing hormone (LH), they don’t measure the hormone that confirms your ovulation, which is progesterone metabolite PdG. Inito…